Plant Name: Licaria chrysophylla
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| GPBAR1; ADORA3; ADRA2B; | |
| PTPN1; | |
| RECQL; TDP1; MTOR; PKM; HSD17B1; CBR1; AKR1B1; HSD17B10; AKR1B10; NOX4; AKR1C4; ALDH1A1; ALOX15; USP2; TNKS2; TNKS; AKR1C3; AKR1C2; | |
| GAA; BCHE; ACHE; | |
| CFTR; | |
| FYN; GSK3B; SYK; MAPK1; FLT3; EGFR; ERBB2; CDK6; CDK8; LCK; CSNK2A1; CDK9; | |
| CA2; CA1; CA12; CA9; CA14; CA5B; CA4; CA7; CA3; CA5A; CA6; | |
| AR; | |
| ESR2; ESR1; | |
| NR1H4; | |
| MAOA; PTGS2; XDH; | |
| MMP9; MMP1; MMP2; | |
| TP53; HIF1A; NFKB1; | |
| ABCG2; ABCC1; | |
| SLC6A2; | |
| LMNA; RAB9A; NPC1; THPO; MAPT; GMNN; APP; TTR; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | AKR1C4 | Aldo-keto reductase family 1 member C4 | P17516 | CHEMBL4999 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | AKR1C3 | Aldo-keto-reductase family 1 member C3 | P42330 | CHEMBL4681 |
| Enzyme_unclassified | AKR1C2 | Aldo-keto reductase family 1 member C2 | P52895 | CHEMBL5847 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.638E-11 | 8.109E-09 | CA2, CA7, CFTR, EGFR, HIF1A, MAPK1, NPC1, NPSR1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.720E-11 | 8.322E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0044597; daunorubicin metabolic process | 7.641E-11 | 3.081E-08 | AKR1B1, AKR1B10, AKR1C2, AKR1C3, AKR1C4 |
| BP | GO:0008152; metabolic process | GO:0044598; doxorubicin metabolic process | 7.641E-11 | 3.081E-08 | AKR1B1, AKR1B10, AKR1C2, AKR1C3, AKR1C4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.913E-10 | 6.829E-08 | CA2, CA7, CDK6, CFTR, EGFR, FYN, HIF1A, LCK, MAPK1, NPC1, NPSR1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.034E-10 | 7.030E-08 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, MMP1, MMP2, MMP9, NR1H4, PTPN1, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.415E-10 | 1.062E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.818E-09 | 7.575E-07 | ABCG2, ACHE, APP, BCHE, CSNK2A1, EGFR, ERBB2, ESR1, ESR2, FLT3, FYN, LCK, MAPK1, MAPT, MMP9, MTOR, NFKB1, PKM, PTGS2, RAB9A, SMN1, SMN2, TP53, TTR, USP2, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.492E-09 | 1.164E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.958E-09 | 1.255E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0001758; retinal dehydrogenase activity | 1.153E-08 | 2.612E-06 | AKR1B10, AKR1C3, AKR1C4, ALDH1A1 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.031E-08 | 4.252E-06 | AKR1C2, AKR1C3, EGFR, ERBB2, FYN, LCK, MTOR, NOX4, THPO |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.656E-08 | 5.433E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.172E-08 | 6.336E-06 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.362E-08 | 8.259E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 9.287E-08 | 1.592E-05 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.604E-07 | 2.568E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.143E-07 | 3.357E-05 | AKR1C3, CYP1A2, EGFR, MAPK1, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0071395; cellular response to jasmonic acid stimulus | 3.164E-07 | 4.623E-05 | AKR1C2, AKR1C3, AKR1C4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.164E-07 | 4.623E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 4.463E-07 | 6.151E-05 | AKR1B1, AKR1C3, CYP1B1, EGFR, MAPK1, MMP9, TP53 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.673E-07 | 1.183E-04 | AKR1B1, EGFR, MMP2, MMP9, MTOR, PTGS2 |
| BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 1.487E-06 | 1.713E-04 | ABCG2, AKR1C4, CFTR, NPC1, NR1H4, SLC6A2, SYK |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.742E-06 | 2.935E-04 | BCHE, CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 3.417E-06 | 3.509E-04 | AKR1B1, APP, FYN, GSK3B, NFKB1, PKM, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 3.750E-06 | 3.816E-04 | AKR1B1, CDK6, CFTR, CYP1B1, EGFR, MAPK1, NFKB1, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 6.292E-06 | 5.880E-04 | AKR1C4, CYP19A1, CYP3A4, ESR1 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 6.540E-06 | 5.933E-04 | APP, EGFR, MAPT |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 6.540E-06 | 5.933E-04 | EGFR, ERBB2, SYK |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 7.009E-06 | 6.255E-04 | ADORA3, APP, AR, CYP1B1, ESR1, ESR2, MAPK1, NFKB1, NR1H4, SYK |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 7.579E-06 | 6.682E-04 | AKR1B1, AKR1C4, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0008152; metabolic process | GO:0042572; retinol metabolic process | 8.366E-06 | 7.258E-04 | AKR1C3, ALDH1A1, CYP1B1, TTR |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 9.313E-06 | 7.984E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 1.038E-05 | 8.762E-04 | ADRA2B, FLT3, FYN, MTOR, PTPN1, SYK, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.277E-05 | 1.053E-03 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 1.277E-05 | 1.053E-03 | AKR1C3, CBR1, PTGS2 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.472E-05 | 1.183E-03 | ABCC1, ABCG2, CDK6, CDK8, CDK9, CFTR, CSNK2A1, EGFR, ERBB2, FLT3, FYN, GSK3B, LCK, MAPK1, MTOR, PKM, RECQL, SYK, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.662E-05 | 1.318E-03 | ABCC1, CA2, CA4, CA9, EGFR, ERBB2, TSHR |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.697E-05 | 1.335E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071383; cellular response to steroid hormone stimulus | 1.755E-05 | 1.375E-03 | AKR1C3, AR, EGFR, FLT3, NPC1 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.869E-05 | 1.418E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.869E-05 | 1.418E-03 | ACHE, BCHE |
| MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 1.869E-05 | 1.418E-03 | FYN, LCK |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.947E-05 | 1.472E-03 | ADRA2B, EGFR, ERBB2, FLT3, MAPK1, NOX4, PTPN1, SYK |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.131E-05 | 1.589E-03 | ALOX15, EGFR, ERBB2, MTOR, TP53 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 2.131E-05 | 1.589E-03 | FYN, GSK3B, MAPT, MTOR, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 2.160E-05 | 1.605E-03 | AKR1B1, AKR1B10, AKR1C3, AKR1C4, ALDH1A1, ALOX15, APP, AR, CA1, CA2, CA3, CA7, CBR1, CDK6, CFTR, CSNK2A1, ERBB2, FLT3, FYN, GMNN, GSK3B, HIF1A, HSD17B1, LCK, LMNA, MAPK1, MAPT, MTOR, NFKB1, PKM, PTPN1, RAB9A, SMN1, SMN2, SYK, TNKS, TNKS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 2.269E-05 | 1.669E-03 | CSNK2A1, GSK3B, MAPK1, MTOR, TNKS |
| BP | GO:0009987; cellular process | GO:0070372; regulation of ERK1 and ERK2 cascade | 2.541E-05 | 1.851E-03 | ALOX15, APP, EGFR, ERBB2, NOX4, PTPN1, SYK, THPO |
| BP | GO:0007610; behavior | GO:0007612; learning | 2.826E-05 | 2.031E-03 | APP, BCHE, FYN, HIF1A, MTOR, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 2.893E-05 | 2.065E-03 | BCHE, CYP1A1, EGFR, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009112; nucleobase metabolic process | 2.981E-05 | 2.114E-03 | MAPK1, MTOR, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 3.281E-05 | 2.312E-03 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 3.476E-05 | 2.397E-03 | CA2, EGFR, SYK |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.643E-05 | 2.494E-03 | AKR1C3, HIF1A, MMP1, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0019901; protein kinase binding | 4.024E-05 | 2.730E-03 | CDK9, EGFR, ESR1, GSK3B, HIF1A, LCK, MAPK1, MTOR, PTPN1, SYK, TP53 |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 4.093E-05 | 2.768E-03 | APP, EGFR, FYN, LCK, MAPK1, NPC1, PTGS2, SLC6A2 |
| MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 4.265E-05 | 2.857E-03 | CDK8, CDK9, MAPK1 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 5.106E-05 | 3.369E-03 | ADORA3, APP, AR, BCHE, CDK6, CYP1B1, ERBB2, LMNA, NOX4, PTGS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.147E-05 | 3.386E-03 | EGFR, FYN, LCK, SYK |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.163E-05 | 3.386E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.590E-05 | 3.539E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 5.590E-05 | 3.539E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 5.590E-05 | 3.539E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.590E-05 | 3.539E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 5.590E-05 | 3.539E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 5.610E-05 | 3.541E-03 | ALOX15, ESR1, GSK3B, MAPT, MMP1, MTOR, TP53 |
| BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 6.032E-05 | 3.765E-03 | EGFR, ERBB2, FLT3, FYN, LCK, MAPK1, MMP2, MMP9, PTPN1, SYK |
| BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 6.176E-05 | 3.820E-03 | EGFR, MAPT, SYK |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.014E-05 | 4.275E-03 | AR, CDK8, CDK9, ESR1, ESR2, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 7.514E-05 | 4.532E-03 | AKR1B1, AKR1C4, CYP19A1, CYP1A2, NOX4, XDH |
| CC | GO:0043226; organelle | GO:0000242; pericentriolar material | 8.574E-05 | 5.059E-03 | LCK, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 9.048E-05 | 5.309E-03 | HIF1A, LMNA, MTOR, PTGS2, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 9.904E-05 | 5.751E-03 | AKR1C3, HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.115E-04 | 6.289E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.115E-04 | 6.289E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.115E-04 | 6.289E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.115E-04 | 6.289E-03 | ALDH1A1, AR |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 1.180E-04 | 6.505E-03 | ADRA2B, FYN, LCK, MAPK1, SYK |
| BP | GO:0040007; growth | GO:0040008; regulation of growth | 1.213E-04 | 6.668E-03 | APP, AR, CSNK2A1, EGFR, ERBB2, ESR2, HIF1A, MAPT, MTOR, TNKS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0045935; positive regulation of nucleobase-containing compound metabolic process | 1.226E-04 | 6.726E-03 | APP, AR, CDK8, CDK9, EGFR, ERBB2, ESR1, ESR2, HIF1A, MAPK1, MTOR, NFKB1, NOX4, NR1H4, PTPN1, TNKS, TNKS2, TP53, TSHR |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 1.279E-04 | 6.930E-03 | APP, EGFR, HIF1A, MAPK1, MMP9, MTOR, NOX4, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.319E-04 | 7.094E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 1.416E-04 | 7.578E-03 | ADORA3, APP, CSNK2A1, CYP1B1, ESR1, GSK3B, MAPT, MMP9, NFKB1, NR1H4, PTGS2, PTPN1, RAB9A, TNKS, TP53 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.634E-04 | 8.494E-03 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, EGFR, MTOR, NOX4, PTGS2, RAB9A |
| BP | GO:0008152; metabolic process | GO:0046885; regulation of hormone biosynthetic process | 1.703E-04 | 8.807E-03 | AKR1C3, HIF1A, NFKB1 |
| BP | GO:0008152; metabolic process | GO:0061370; testosterone biosynthetic process | 1.853E-04 | 9.297E-03 | AKR1C3, CYP19A1 |
| BP | Unclassified; | GO:0051534; negative regulation of NFAT protein import into nucleus | 1.853E-04 | 9.297E-03 | GSK3B, MTOR |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.853E-04 | 9.297E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.919E-04 | 9.540E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006693; prostaglandin metabolic process | 1.919E-04 | 9.540E-03 | AKR1C2, AKR1C3, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 1.953E-04 | 9.689E-03 | EGFR, ERBB2, FYN, LCK |
| CC | GO:0043226; organelle | GO:0070013; intracellular organelle lumen | 2.010E-04 | 9.901E-03 | APP, BCHE, CA5A, CA5B, EGFR, FLT3, GAA, HSD17B10, MAPK1, MMP9, NFKB1, PKM, PTGS2, TP53, TTR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.167E-24 | 1.561E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.802E-19 | 2.760E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.224E-16 | 7.800E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.403E-23 | 7.926E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.586E-11 | 4.314E-09 | GSK3B; FLT3; MMP1; MMP2; PTGS2; HIF1A; MMP9; EGFR; NFKB1; MTOR; AR; CDK6; ERBB2; MAPK1; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.358E-12 | 2.122E-10 | HSD17B1; CYP1A2; CYP1A1; AKR1C3; CYP1B1; AKR1C2; AKR1C4; CYP3A4; CYP19A1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.984E-11 | 3.590E-09 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; AKR1C2; CYP3A4; CYP2C19; PTGS2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.673E-10 | 1.102E-08 | PKM; FLT3; ERBB2; MAPK1; TP53; HIF1A; EGFR; MTOR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.579E-10 | 1.102E-08 | MMP1; MMP2; ERBB2; MAPK1; MMP9; TP53; EGFR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.692E-09 | 9.493E-08 | GSK3B; AR; ERBB2; MAPK1; TP53; EGFR; NFKB1; MTOR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.570E-08 | 1.028E-06 | ABCC1; CDK6; ERBB2; CYP1B1; MAPK1; PTGS2; TP53; MMP9; EGFR; NFKB1; MTOR |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.416E-07 | 2.316E-06 | CBR1; MAOA; GAA; ALOX15; AKR1C3; AKR1B1; AKR1C4; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; CYP2C9; PKM; AKR1B10; HSD17B1; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.276E-08 | 1.255E-06 | HSD17B1; CYP1A1; AKR1C3; CYP1B1; PTGS2; CYP19A1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.827E-07 | 2.740E-06 | MMP2; ERBB2; MAPK1; TP53; HIF1A; ESR1; MMP9; EGFR; MTOR |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.332E-07 | 3.230E-06 | CYP2C9; CBR1; ALOX15; AKR1C3; CYP2C19; PTGS2 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.402E-07 | 4.373E-06 | CDK6; ERBB2; MAPK1; TP53; EGFR; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.538E-07 | 5.446E-06 | CYP2C9; APP; MAOA; ALOX15; MAPK1; CYP2C19; PTGS2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.686E-06 | 1.686E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; FYN; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.226E-07 | 7.004E-06 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 6.752E-07 | 7.150E-06 | PTPN1; CSNK2A1; ERBB2; MAPK1; FYN; EGFR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.271E-07 | 2.288E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.757E-06 | 3.220E-05 | MMP2; MAPK1; ESR1; MMP9; EGFR; ESR2 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.740E-06 | 3.220E-05 | CDK6; ERBB2; MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.579E-06 | 2.443E-05 | GSK3B; ERBB2; MAPK1; TP53; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.730E-06 | 3.870E-05 | ERBB2; MAPK1; HIF1A; EGFR; NFKB1; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.852E-06 | 5.889E-05 | CDK6; MAPK1; TP53; EGFR; MTOR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.037E-05 | 7.300E-05 | GSK3B; MAPK1; TP53; ESR1; HIF1A; MTOR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.142E-05 | 7.612E-05 | ABCC1; ADORA3; MAPK1; FYN; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.852E-06 | 5.889E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.300E-05 | 8.068E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.054E-05 | 7.300E-05 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 9.300E-05 | 4.923E-04 | GSK3B; CDK6; SYK; MAPK1; TP53; EGFR; NFKB1; MTOR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.268E-05 | 1.897E-04 | GSK3B; ERBB2; MAPK1; EGFR; MTOR |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.214E-05 | 7.801E-05 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.691E-05 | 4.195E-04 | GSK3B; LCK; MAPK1; FYN; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.254E-04 | 1.076E-03 | CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.506E-05 | 2.535E-04 | SYK; CSNK2A1; LCK; PTGS2; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.360E-04 | 1.083E-03 | SYK; LCK; MAPK1; FYN; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.444E-04 | 1.083E-03 | GSK3B; MAPK1; TP53; EGFR; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.760E-04 | 1.504E-03 | CDK6; MAPK1; TP53; MMP9; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.529E-04 | 1.444E-03 | SYK; MAPK1; FYN; EGFR; MTOR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.653E-05 | 4.964E-04 | FLT3; MAPK1; NFKB1; MTOR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.271E-04 | 1.076E-03 | CDK6; MAPK1; TP53; EGFR |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.528E-04 | 1.083E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.528E-04 | 1.083E-03 | GSK3B; SYK; MAPK1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 7.124E-04 | 2.728E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.711E-04 | 3.496E-03 | CDK9; FLT3; TP53; MMP9; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 8.674E-04 | 3.186E-03 | MAPK1; HIF1A; EGFR; MTOR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.619E-03 | 5.281E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.732E-04 | 1.851E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.619E-03 | 5.281E-03 | GSK3B; ERBB2; MAPK1; FYN; EGFR |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.358E-05 | 1.415E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.192E-03 | 4.048E-03 | MAPK1; PTGS2; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.152E-03 | 3.989E-03 | PTPN1; GSK3B; NFKB1; MTOR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.643E-03 | 5.281E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.878E-03 | 8.493E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 2.524E-03 | 7.700E-03 | SYK; LCK; MAPK1; FYN |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 4.413E-03 | 1.222E-02 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.805E-03 | 8.414E-03 | PTPN1; GSK3B; MAPK1; MTOR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.882E-03 | 2.435E-02 | MAPK1; CFTR; NFKB1; TSHR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.862E-03 | 2.247E-02 | MMP2; MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 6.656E-03 | 1.762E-02 | MMP2; MAPK1; EGFR |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.145E-02 | 2.747E-02 | ACHE; MAPK1; FYN |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.475E-02 | 3.492E-02 | SYK; MAPK1; FYN |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 7.279E-03 | 1.899E-02 | TP53; NFKB1; MTOR |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.199E-02 | 4.886E-02 | GSK3B; CSNK2A1; TP53 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.942E-03 | 8.542E-03 | SYK; MAPK1; FYN |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.540E-02 | 3.599E-02 | GSK3B; CDK6; TP53 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.640E-02 | 3.738E-02 | GSK3B; MAPK1; FYN |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.058E-03 | 6.499E-03 | MAPK1; HIF1A; MTOR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.597E-03 | 1.028E-02 | MAPK1; PTGS2; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.261E-03 | 7.017E-03 | GSK3B; MAPK1; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.079E-03 | 3.807E-03 | PKM; MAPK1; MTOR |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 8.359E-04 | 3.135E-03 | ABCC1; CFTR; ABCG2 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.242E-02 | 4.920E-02 | GSK3B; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.673E-04 | 1.119E-03 | AKR1B10; GAA; AKR1B1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.804E-02 | 4.059E-02 | MAOA; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.601E-02 | 3.694E-02 | CYP3A4; XDH |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 9.480E-03 | 2.370E-02 | MAPK1; FYN |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 6.575E-03 | 1.762E-02 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 5.715E-03 | 1.559E-02 | MAPK1; EGFR |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 7.967E-03 | 2.049E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.001E-02 | 2.435E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.164E-03 | 1.171E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.729E-04 | 8.644E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; CA1; CA1; ACHE; AKR1B1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOA; MAOA |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; SYK; SYK; ERBB2; CBR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Gastric cancer | C16 | ERBB2; EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK; SYK; ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; ERBB2; EGFR; EGFR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; SLC6A2; MAOA |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; MAOA |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; MTOR; FLT3; EGFR; MMP2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; ERBB2 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; GSK3B; APP; ACHE; ACHE; ACHE; MAOA; MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; MAPK1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; GPBAR1; NFKB1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ERBB2; EGFR; ESR1; AKR1C3 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; AR; GSK3B; HIF1A; SYK; TP53; ADORA3; CA1; MTOR; FLT3; FLT3; CA9; MAPK1; APP; MMP9; ERBB2; ERBB2; ACHE; EGFR; ESR1; ESR1; MMP2; CSNK2A1; NFKB1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; MMP2 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; ERBB2; ERBB2; ERBB2; EGFR; EGFR; EGFR; ESR1; ESR1 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; MTOR; FLT3; CA9; MAPK1; MMP9; ERBB2; EGFR; PKM; MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; SLC6A2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; MTOR; ERBB2; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; SYK; MMP1; AKR1B1 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; MTOR; EGFR; EGFR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; MTOR; ERBB2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP; EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | ERBB2; EGFR; EGFR |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; XDH; AKR1B1; ABCC1; ABCC1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; ESR1; NPSR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; ADRA2B; MAOA |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; AR; MTOR; ACHE; ESR1; PKM; SLC6A2 |
| H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; MMP2 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; MMP2 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; MMP1; ABCC1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; MTOR; CA9; ERBB2; EGFR |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; SYK; MTOR |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |